Epidermolysis Bullosa Acquisita (EBA) is a chronic autoimmune blistering disease of the skin and mucus membranes. Epidermolysis bullosa acquisita is characterized clinically by blisters, scars, and cysts primarily at the trauma-prone areas. EBA blisters tend to be localized to areas that are easily injured such as the hands, feet, knees, elbows, and buttocks. Sometimes there is mucosal involvement with blisters forming in the mouth, nose and eyes.
Epidermolysis bullosa (EB) is the name given to a group of inherited blistering diseases that are present from birth. Unlike EB, EBA is not inherited and usually presents in adult life. Current evidence points to EBA being an autoimmune blistering disease.
EBA usually occurs in the fourth and fifth decade of life. Males and females of all races can be affected.
The primary aim in the treatment of EBA is to protect the skin and stop blister formation, promote healing and prevent complications.
Since EBA is considered an autoimmune disease it is reasonable to use immunosuppressive agents to modify or reduce autoimmune responses and decrease the production of autoantibodies.
EBA is a chronic inflammatory disease that has periods of partial remissions and exacerbations. If treated and cared for properly, patients can expect to live a normal lifespan.